Promis Diagnostics, Inc
1 known investors
Promis Diagnostics develops noninvasive tests for early detection of colorectal, bladder, and lung cancer using its patented LTE-qMSP technology, which uses methylated DNA as biomarkers via PCR. The company targets patients seeking accessible and affordable cancer screening options.
Investors · 1
Competitors · 5
by search overlapCareDx7 shared keywordsCareDx provides molecular diagnostic testing, workflow software, patient support, and pharmacy services for care teams working in transplant, cell therapy, and specialty oncology. Its products support rejection monitoring and complex care management in precision medicine.
MDxHealth6 shared keywordsmdxhealth develops molecular diagnostic tests for urologic diseases, with a focus on prostate cancer. Its products—Confirm mdx, GPS mdx, and Exo mdx—help physicians assess cancer risk, address false-negative biopsies, and guide treatment decisions for patients.
Foresight Dx6 shared keywordsForesight Diagnostics develops ultra-sensitive molecular diagnostic tests that combine genomics and bioinformatics to detect minimal residual disease and circulating tumor DNA across multiple cancer types. Its offerings support oncology drug development, clinical trials, and patient care for academic and biopharma partners.
Pinkdx5 shared keywordsPinkDx is a diagnostics company developing tests, led by a leadership team spanning scientific, medical, and business functions.
Earlydx5 shared keywordsEarlyDx develops non-invasive liquid biopsy tests aimed at early cancer detection and precision medicine. The company positions its tests as accurate and affordable diagnostics.
Companies competing with Promis Diagnostics, Inc for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Promis Diagnostics, Inc do?
- Promis Diagnostics develops noninvasive tests for early detection of colorectal, bladder, and lung cancer using its patented LTE-qMSP technology, which uses methylated DNA as biomarkers via PCR. The company targets patients seeking accessible and affordable cancer screening options.
- Who are Promis Diagnostics, Inc's investors?
- Promis Diagnostics, Inc's investors include Solidus Investment.